The A-BRAVE trial evaluated the efficacy of avelumab, an anti-programmed death-ligand 1 (PD-L1) antibody, as adjuvant treatment of patients with early triple-negative breast cancer (TNBC) at high risk.
A-BRAVE trial: a phase III randomized trial with anti-PD-L1 avelumab in high-risk triple-negative early breast cancer patients
Annals of Oncology | | P.F. Conte, M.V. Dieci, G. Bisagni, P. Schmid, A. Zambelli, F. Piacentini, M. De Laurentiis, A.G. Favaretto, S. Tamberi, G.V. Bianchi, C. Zamagni, S. Cinieri, D.C. Corsi, L. Del Mastro, A. Ferro, A. Gennari, M. Mion, A. Musolino, L. Nicolé, P. Del Bianco, G.L. De Salvo, V. Guarneri
Topics: breast-cancer, immunotherapy, clinical-trials